Clinical Trials
2 trialsNCT06589804 2026-06-03
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06706401 2026-04-24
LYSARI
Centre Leon Berard
Phase 3 Recruiting